Program
imetelstat
Also written as “Imetelstat Sodium (GRN163L)”, “Imetelstat” and “Imetelstat sodium”.
Its studies are mostly in Primary Myelofibrosis · Multiple Myeloma · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Thrombocythemia, Essential, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Geron | 154 open or running | phase 4since Nov 3, 2026 | Jul 25, 2005 | Feb 2027phase 1 · NCT05371964 |
| GCP-Service International West | 10 open or running | phase 2since Oct 13, 2022 | Oct 13, 2022 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Jul 25, 2005.
- Apr 4, 2006Phase 1 study in RecurrenceGeron · NCT00310895 · 85 enrolled · United States
- Jul 31, 2007Phase 1 study in Lung NeoplasmsGeron · NCT00510445 · 27 enrolled · United States
- Jan 3, 2008Phase 1 study in Multiple MyelomaGeron · NCT00594126 · 20 enrolled · United States
- Jul 16, 2008Phase 1 study in Multiple MyelomaGeron · NCT00718601 · 40 enrolled · United States
- Aug 7, 2008Phase 1 study in Breast NeoplasmsGeron · NCT00732056 · 24 enrolled · United States
- Jun 3, 2010Phase 2 study in Carcinoma, Non-Small-Cell LungGeron · NCT01137968 · 116 enrolled · United States, Canada, Germany
- Nov 11, 20102 phase 2 studiesGeron · NCT01243073, NCT01242930
- Nov 18, 2012Phase 2 study in Primary MyelofibrosisGeron · NCT01731951 · 80 enrolled · United States
- Apr 21, 2015Phase 2 study in Primary MyelofibrosisGeron · NCT02426086 · 107 enrolled · United States, Belgium, Canada and more
- Oct 27, 2015Phase 3 study in Myelodysplastic SyndromesGeron · NCT02598661 · 289 enrolled · United States, Belgium, Canada and more
- Sep 18, 2020Phase 3 study in Primary MyelofibrosisGeron · NCT04576156 · 327 enrolled · United States, Argentina, Australia and more
- May 5, 2022Phase 1 study in Primary MyelofibrosisGeron · NCT05371964 · 30 enrolled · United States
- Oct 13, 2022GCP-Service International West's first study: phase 2 study in Myelodysplastic SyndromesNew to GCP-Service International WestGCP-Service International West · NCT05583552 · 46 enrolled · Australia, France, Germany
- Nov 3, 2026Phase 4 study in Anemia, Refractory, with Excess of BlastsGeron · NCT07939451 · 100 planned
Ahead
- Feb 2027Primary completion: phase 1 study in Primary MyelofibrosisGeron · NCT05371964
- Jun 30, 2028Primary completion: phase 3 study in Primary MyelofibrosisGeron · NCT04576156
- Jul 2030Primary completion: phase 4 study in Anemia, Refractory, with Excess of BlastsGeron · NCT07939451
TargetBeta
“Telomerase reverse transcriptase inhibitor”ChEMBL 37, by rule
Other programs on TERT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-TERT/Anti-CD3 T-cell Engager CBX-663rule | crossbow-therapeutics-inc | phase 1 | 1 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07939451Anemia, Refractory, with Excess of Blasts | 4 | Not yet recruiting | Geron | Jul 2030 | 100 |
| NCT05583552Myelodysplastic Syndromes · Australia, France, Germany | 2 | Completed | GCP-Service International West | Mar 27, 2025 | 46 |
| NCT05371964Primary Myelofibrosis · United States | 1 | Active, not recruiting | Geron | Feb 2027 | 30 |
| NCT04576156Primary Myelofibrosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Geron | Jun 30, 2028 | 327 |
| NCT02598661Myelodysplastic Syndromes · United States, Belgium, Canada and more | 3 | Active, not recruiting | Geron | Oct 13, 2023 | 289 |
| NCT02426086Primary Myelofibrosis · United States, Belgium, Canada and more | 2 | Completed | Geron | Apr 26, 2018 | 107 |
| NCT01731951Primary Myelofibrosis · United States | 2 | Completed | Geron | May 24, 2018 | 80 |
| NCT01242930Multiple Myeloma · United States | 2 | Completed | Geron | Nov 2014 | 13 |
| NCT01243073Thrombocythemia, Essential · United States, Germany, Switzerland | 2 | Completed | Geron | Oct 2013 | 20 |
| NCT01137968Carcinoma, Non-Small-Cell Lung · United States, Canada, Germany | 2 | Completed | Geron | Sep 2013 | 116 |
| NCT00732056Breast Neoplasms · United States | 1 | Completed | Geron | Sep 2011 | 24 |
| NCT00718601Multiple Myeloma · United States | 1 | Completed | Geron | Oct 2011 | 40 |
| NCT00594126Multiple Myeloma · United States | 1 | Completed | Geron | Jul 2011 | 20 |
| NCT00510445Lung Neoplasms · United States | 1 | Completed | Geron | Apr 2011 | 27 |
| NCT00310895Recurrence · United States | 1 | Completed | Geron | Mar 2013 | 85 |
| NCT00124189Leukemia, Lymphocytic, Chronic, B-Cell · United States | 1 | Completed | Geron | Mar 2013 | 48 |
How it is read
Names in the registry
- “Imetelstat Sodium (GRN163L)”, 4 entries
- “Imetelstat”, 3 entries
- “Imetelstat sodium”, 2 entries
- “GRN163L”, 2 entries
- “Imetelstat (3.55 mg/kg)”, 1 entry
Conditions, from the studies’ own filings
- Primary Myelofibrosis, 4 studies
- Multiple Myeloma, 3 studies
- Myelodysplastic Syndromes, 2 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Thrombocythemia, Essential, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.